. Mnt is detected in nuclei of adult skeletal muscle (A) and adipose tissue (C) from wildtype flies but not from Mnt-/-null flies (B, D, E). Scale bar is 20 µm. In (E), relative Mnt mRNA levels are shown with SEM indicated and n=4. ***P<0.001, unpaired two-tailed Student's t-test. (F) No apparent changes in Mnt and myoglianin mRNA levels are detected in muscle during aging and in response to starvation and a 5% sucrose diet. Mnt activity and Myoglianin signaling may be modulated via post-transcriptional mechanisms during aging independently from gene expression. Average body weight and (B) thoracic weight (consisting mostly of skeletal muscle and hence indicative of muscle mass) of flies overexpressing Mnt (blue) or myoglianin (green), and with myoglianin RNAi#1 and myoglianin RNAi#2 (red and orange) in muscle in comparison with controls (grey). SEM is indicated and n(batches of 10 flies)=3. No significant changes were detected by two-way ANOVA and Tukey's post test. (C) Relative food intake estimated with the capillary feeding (CAFÉ) assay reveals no substantial differences in the food intake of the genotypes analyzed. SEM and n(measurements) are indicated. (Figure 3 ) are ordered by ascending median lifespan with each box outlining the middle 50% of survival times for flies in each RNAi treatment, and whiskers outlining the middle 80% of survival times. RNAi treatments significantly increasing lifespan relative to controls (RNAi against the white; HMS17) are represented by red boxes, and treatments significantly decreasing lifespan are represented by green boxes (log-rank test; FDR-adjusted P<0.05 with at least a 5% change in median lifespan). The vertical yellow region outlines the middle 50% of survival times in the control treatment (HSM17). Two different RNAi treatments in skeletal muscles against the TGF-β ligand myoglianin significantly shortened the median lifespan as compared with RNAi against white (HMS17). Right panel: Percentage of flies with climbing defects at days 36 (violet) and 56 (black). A green asterisk is used to denote cohorts for which the percentage of flies with climbing defects at day 56 is significantly higher than in controls at day 56 (chi-square test; FDR-adjusted P<0.05). Myoglianin RNAi significantly increases the percentage of flies with climbing defects in old age. None of the RNAi treatments resulted in climbing defects in young age (day 8; Figure 3 ). (A) Absence of changes in P-p38 MAPK levels in UAS-transgene alone controls. Western blot analysis of phospho-p38 (P-p38) MAPK levels in thoraces from heterozygous flies carrying UAS-transgenes but no Mhc-Gal4. Normalization of P-p38 MAPK levels with α-tubulin levels (loading control) indicates the lack of changes in P-p38 MAPK levels in the absence of Gal4-driven transgene expression. (B) Western blot analysis of phospho-p70 S6K and total p38 MAPK levels in response to Mnt and myoglianin overexpression and RNAi in muscle. No substantial changes were detected, indicating that Mnt/Myoglianin signaling regulates phosphorylation of p38 MAPK (Figure 7) but not total p38 MAPK protein levels and phospho-p70 S6K levels. (C) Myoglianin RNAi in muscle overexpressing Mnt results in lower P-p38 MAPK levels in thoraces and heads and abdomens when compared to white RNAi (control). See also Figure 7 .
EXTENDED EXPERIMENTAL PROCEDURES

Fly Stocks
The following fly stocks were used: ppl-Gal4 (Colombani et al., 2003) ; Mhc-Gal4 (Schuster et al., 1996) ; dMef2-Gal4 (Ranganayakulu et al., 1996) (Ni et al., 2009; Ni et al., 2011) ) and are indicated in Figures S5 .
Construction of UAS-myoglianin
To generate UAS-myoglianin, the Drosophila melanogaster myoglianin (CG1838) coding sequence, corresponding to nucleotides 844-2640 of sequence AY061367, was amplified by PCR using the full-length cDNA clone LD29161 as template with primers 5'-gccagatctatgctggccaactcatgctgcggttgg-3' and 5'-gccctcgagctaagaacag ctgcaaccctcgacagac-3' (underlined are BglII and XhoI restriction sites, respectively). The PCR product was cut with BglII and XhoI for cloning into the pUAST vector, followed by sequencing and injection into y 1 w 1118 embryos.
Capillary Feeding (CAFÉ) Assays
For capillary feeding (CAFÉ) assays (Ja et al., 2007) , groups of 10 flies were transferred twelve hours before the assay from standard food to 1.5% agar vials and fed a 5% sucrose solution in PBS provided via a 5 µl calibrated glass micropipette (VWR, . At the start of the assay, the old micropipette was replaced with a new one and the amount of liquid food consumed was recorded every 2 hours and corrected on the basis of the evaporation observed in a vial without flies.
Muscle and Body Weight Measurements
For measurement of body weight, 3 groups of 10 flies were weighted on a precision balance and the average body weight calculated. For measurement of thoracic weight (indicative of muscle mass), 3 groups of 10 thoraces were weighted and the average weight calculated.
Immunostaining, Laser Scanning Confocal Microscopy, and Image Analysis Dissected tissues were fixed for 20 minutes in PBS with 4% paraformaldehyde and 0.1% Triton X-100, washed, and incubated overnight with 1:100 dilution of anti-Fibrillarin (Nop1p; Encore Biotechnology #MCA-38F3) or mouse anti-Mnt (P5D6) (Loo et al., 2005) . The following day, samples were washed and incubated overnight with DAPI (Invitrogen, 1µg/mL), Alexa555-conjugated secondary antibodies (Molecular Probes, 1:200) , and Alexa635-conjugated Phalloidin (Molecular Probes, 1:100). Samples were imaged with a Leica SP2 confocal microscope. Image analysis was done with the "Analyze particle" function of ImageJ.
Luciferase Assays
Luciferase assays were done as before (Demontis and Perrimon, 2010) . 15×10 4 S2R+ cells/cm 2 were seeded in Schneider's medium (Gibco) containing 10% FCS and transfected one day later using the Effectene Transfection Kit (Qiagen). The following day the medium was changed and, after an additional 3 days in culture, the luciferase assay was performed with the Dual-Glo Luciferase Assay (Promega) according to manufacturer's instructions. The CG4364-and CG5033-firefly luciferase reporters were previously described (Hulf et al., 2005) . To generate the myoglianin-Renilla luciferase reporter, the proximal promoter region (>4:718244,716674) of the myoglianin gene (CG1838) was amplified by PCR and cloned into the pRL-null vector (Promega) with XhoI and EcoRI. UAS-Mnt and UAS-YFP plasmids for overexpression of either Mnt (CG13316) or yellow fluorescent protein (YFP) were provided by the DRSC at Harvard Medical School. In experiments with the myoglianin-Renilla luciferase reporter, an actin-firefly luciferase reporter was co-transfected as normalization control and luciferase activity refers to ratio of Renilla to firefly luciferase activity. In experiments with the CG4364-and CG5033-firefly luciferase reporters (Hulf et al., 2005) , an actinRenilla luciferase reporter was co-transfected as normalization control and luciferase activity refers to ratio of firefly to Renilla luciferase activity. S2R+ cells were also co-transfected with either UAS-YFP (control) or UAS-Mnt as indicated.
Western Blots
Samples were prepared by homogenizing in a bullet blender (NextAdvance) either fly thoraces (consisting mainly of muscles) or heads and abdomens (consisting mainly of non-muscle tissues) from at least 15 male flies per group in RIPA buffer with protease and phosphatase inhibitors. SDS-PAGE was done as previously (Demontis and Perrimon, 2010) . Primary antibodies used are anti-Pp38 MAPK (Cell Signaling Technologies #9215), anti-Drosophila P-p70 S6K (Cell Signaling Technologies #9209), anti-total p38 MAPK (Cell Signaling Technologies #9212), and anti-α-Tubulin (Cell Signaling Technologies #2125). For densitometry of Western blots, band intensity was quantified with the Histogram function of Photoshop.
Bioinformatic Analysis
Multiple sequence alignment and phylogenetic analysis were done with ClustalW, available at http://www.ebi.ac.uk/Tools/msa/clustalw2/, and orthology prediction with DIOPT, available at http://www.flyrnai.org/cgi-bin/DRSC_ orthologs.pl.
